Abstract
In this claims analysis, vernal keratoconjunctivitis (VKC) patients (≤18 years) treated with immunomodulators or corticosteroids had more corneal complications and higher ophthalmic care costs versus matched non-VKC controls, indicating a need for more effective treatments.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
